

cefaZOLIN

BRAND NAME CEFAZOLIN AFT, ALPHAPHARM, HOSPIRA, JUNO

DRUG CLASS Cephalosporin antibiotic

AVAILABILITY Vial contain 500 mg, 1 g or 2 g of cefazolin as cefazolin sodium. Each 1 g contains 2.1 mmol of sodium.¹

WARNING Contraindicated in patients with severe immediate (IgE mediated) or severe delayed (T-cell mediated) hypersensitivity to penicillins. Seek specialist advice for patients with non-severe immediate hypersensitivity to penicillins.

pH 4.5–6 when reconstituted¹

PREPARATION **For IM use:** reconstitute the 500 mg vial with 2 mL and the 1 g vial with 2.5 mL of water for injections or lidocaine 0.5%. Shake well and warm in the hands to aid dissolution. Final volumes are 2.2 mL and 3 mL and the approximate concentrations are 225 mg/mL and 330 mg/mL respectively.¹ Do not reconstitute the vial with sodium chloride 0.9% as small crystals may form and they may be difficult to see.² Solutions reconstituted with lidocaine must not be injected intravenously.

For IV use: reconstitute the vial with at least 10 mL of water for injections.¹ If a part-dose is required, use the following table to reconstitute the vial:

Vial size	Volume of water for injections	Concentration
500 mg	4.8 mL	100 mg/mL
1 g	9.5 mL	100 mg/mL
2 g	19 mL	100 mg/mL

For intracameral use: must be reconstituted and diluted under aseptic conditions, preferably by pharmacy.

The solution is clear and light yellow.²

Powder volume: 500 mg – 0.2 mL, 1 g – 0.5 mL, 2 g – 1 mL.^{1,3}

STABILITY Vial: store below 25 °C. Protect from light.¹

Reconstituted solution: stable for 24 hours at 2 to 8 °C.¹ Crystals may form if the solution is refrigerated. Redissolve by shaking the vial and warming in the hands.¹

Infusion solution: stable for 24 hours below 25 °C.²

For CoPAT use: stable for 24 hours at 37 °C.⁴ (based on a solution of 72.2 mg/mL in water for injections). Infusion solutions prepared in a sterile production unit are stable for more than 7 days at 2 to 8 °C.²

ADMINISTRATION

IM injection Suitable¹

SUBCUT injection Not recommended

IV injection Inject slowly over 3 to 5 minutes.¹ A dose of 2 g can be given over at least 5 minutes.

IV infusion Dilute the dose with 50–100 mL of a compatible fluid and infuse over 10 to 60 minutes.¹ Suitable for doses of 2 to 4 g given once or twice daily.⁵

Doses of 6 to 8 g are given as a 24 hour continuous infusion in the community setting.⁵

IV use for infants and children Reconstitute to 100 mg/mL or weaker and inject over 3 to 5 minutes. For IV injection in fluid-restricted patients a concentration of 142 mg/mL in water for injections has been used.⁶ Or dilute to 20 mg/mL and infuse over 10 to 60 minutes.⁷

Other Suitable for intracameral injection during eye surgery. Very low doses are used and special preparation is required.⁸

continued over the page

COMPATIBILITY

- Fluids** Glucose 5%¹, glucose 10%¹, glucose in sodium chloride solutions¹, Hartmann's¹, Plasma-Lyte 148 via Y-site⁹, Ringer's¹, sodium chloride 0.9%¹
- Y-site** Aciclovir², amifostine², anidulafungin², atracurium^{2,10}, aztreonam^{2,10}, bivalirudin², buprenorphine¹⁰, calcium gluconate¹⁰, ciclosporin¹⁰, clindamycin¹⁰, dexamethasone¹⁰, dexmedetomidine², digoxin¹⁰, esmolol^{2,10}, fentanyl¹⁰, filgrastim², fluconazole^{2,10}, foscarnet², furosemide¹⁰, glyceryl trinitrate¹⁰, granisetron², heparin sodium^{2,8}, hydrocortisone sodium succinate¹⁰, indomethacin¹⁰, lidocaine¹⁰, linezolid², methylprednisolone sodium succinate¹⁰, metoclopramide¹⁰, midazolam^{2,10}, morphine sulfate^{2,10}, nicardipine², noradrenaline (norepinephrine)¹⁰, palonosetron², pethidine², potassium chloride¹⁰, ranitidine¹⁰, remifentanyl², sodium bicarbonate¹⁰, sodium nitroprusside¹⁰, suxamethonium¹⁰, vecuronium², verapamil¹⁰

INCOMPATIBILITY

Fluids No information

Drugs Aminoglycosides: amikacin, gentamicin, tobramycin¹, ascorbic acid², azathioprine¹¹, calcium chloride¹¹, caspofungin², cefotaxime¹¹, dobutamine¹¹, dopamine¹¹, erythromycin¹¹, ganciclovir¹¹, haloperidol lactate¹¹, hydralazine¹¹, isavuconazole², mivacurium¹¹, mycophenolate mofetil¹¹, pentamidine², phentolamine¹¹, promethazine², protamine¹¹, pyridoxine¹¹, rocuronium¹, sodium ascorbate¹

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 15/05/2021.
2. McEvoy GK editor. Handbook on injectable drugs. 20th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2018.
3. AFT Quality assurance. Displacement values [email]. North Ryde, NSW: AFT Pharmaceuticals. 30/10/2019.
4. Bing CD, Nowobilski-Vasiliois A. Extended stability for parenteral drugs. 6th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2017.
5. Antibiotic stability and preparation in community-based parenteral antimicrobial therapy [April 2019]. In: eTG complete [internet]. Melbourne: Therapeutic Guidelines Ltd; March 2021.
6. Phelps S, Hagemann TM, Lee KR, Thompson AJ. Pediatric injectable drugs. 11th ed. Bethesda, MD: Am Soc Health-System Pharmacists; 2018.
7. Taketomo C, Hodding J, Kraus D. Pediatric and neonatal dosage handbook. 26th ed. Hudson, OH: Am Pharm Association. Lexicomp; 2019-2020.
8. Surgical prophylaxis for ophthalmic surgery [March 2021]. In: eTG complete [internet]. Melbourne: Therapeutic Guidelines Ltd; March 2021.
9. OneCall Medical Information Service. Y-Site compatibility of intravenous drugs with Plasmalyte 148. Toongabbie, NSW: Baxter; 2015.
10. Trissel LA, Leissing NC. Trissel's Tables of physical compatibility. Lake Forest IL: Multimatrix; 1996.

11.Cefazolin. In: IV index [internet]. Trissel's 2 clinical pharmaceuticals database (parenteral compatibility). Greenwood Village, CO: Truven Health Analytics. Accessed 02/10/2019.